ADVFN - Advanced Financial Network.
HOME» NASDAQ » T » TEVA Stock Price » TEVA Stock News

Teva Pharmaceutical Share News

 Teva Pharmaceutical Industries Limited (mm) Stock Price
TEVA Stock Price
 Teva Pharmaceutical Industries Limited (mm) Stock Chart
TEVA Stock Chart
 Teva Pharmaceutical Industries Limited (mm) Stock News
TEVA Stock News
 Teva Pharmaceutical Industries Limited (mm) Company Information
TEVA Company Information
 Teva Pharmaceutical Industries Limited (mm) Stock Trades
TEVA Stock Trades

Teva Pharma Reduces 2012 Guidance On Lower Generics View

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) lowered its guidance for 2012 on reduced expectations for generic drug sales in the U.S. and Europe, as well as softer sales of some branded offerings. The world's biggest manufacturer of generic drugs now expects per-share earnings of $5.30 to $5.40 on net sales of $20 billion to $21 billion. The Israel company in December had projected per-share earnings of $5.48 to $5.68 on revenue of $22 billion. The company reduced its outlook for generic drugs to $10.7 billion from its prior view of $11.8 billion. U.S. generic sales are pegged at $4.6 billion, down from $5 billion. Europe sales are seen at $3.4 billion, compared with a prior estimate of $4 billion. The reduced forecast for branded drugs includes its outlook for leukemia drug Treanda and its women's health products. Teva recently reported its first-quarter profit jumped 41%, as strong sales of branded and generic medicines in the U.S. and emerging markets offset a weak performance in Europe. The company's American depositary shares were up 1.4% at $39.10 in premarket trading after trading around $39.50 earlier. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Teva Pharmaceutical (TEVA)
DateTimeHeadline
05/29/201217:52:10FDA Warns About Fake Version Of Teva's ADHD Drug Adderall
05/29/201217:47:50Pronova Wins Heart-Drug Patent Case Against Teva, Par Pharma
05/24/201209:38:21Teva Pharma Reduces 2012 Guidance On Lower Generics View
05/17/201215:17:50FDA Approves Generic Versions Of Blood Thinning Drug Plavix
05/09/201207:17:36Teva Profit Surges In First Quarter On Branded, Generic Drug...
04/30/201203:04:09Consort Gets FDA Approval For Its Integrated Dose Counter
04/26/201210:12:05Mylan 1Q Profit Rises 24%; EpiPen Settlement Reached With Teva
04/24/201208:26:02Watson, Actavis To Unveil EUR4.5 Billion Merger Deal Wednesday
04/05/201213:24:34Mylan Seeks To Overturn FDA's Provigil Decision
04/03/201202:15:49Glenmark Unit Gets US OK To Sell Copy Of Contraceptive Drug
03/29/201218:40:14US Court Rules For AstraZeneca's Seroquel XR Patent
03/29/201206:32:55Teva Revises Pricing On Euro 7-year Bond To Swaps +1.05 Area
03/28/201217:53:08Myriad Genetics Enters Testing Agreement With Teva Subsidiary
03/26/201204:57:02AstraZeneca Loses Bid To Delay Generics Of Seroquel In US Market
03/21/201212:59:07Drug Maker Watson To Buy Actavis For About EUR4.5 Billion - Source
03/21/201210:55:24Teva Pharmaceutical To Switch Listing To NYSE In May
03/14/201214:58:34Teva Receives FDA Approval For Generic Lexapro For Adults
03/08/201210:10:11Teva: FDA Approves Dose Counter For ProAir HFA Asthma Drug
02/21/201207:50:17Mylan 4Q Net Soars On Year-Earlier Items, Improved Margins
02/15/201212:54:13FDA Approves BioSante Gel for Male Low Testosterone; Shares Up

Teva Pharmaceutical and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad